Laparoscopic Surgical Treatment of Aorto-iliac Occlusive Disease (LAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01259908|
Recruitment Status : Active, not recruiting
First Posted : December 14, 2010
Last Update Posted : April 9, 2018
|Condition or disease||Intervention/treatment|
|Aorto Iliac Occlusive Disease||Procedure: Laparoscopic vs open Ygraft|
Patients with aorto-iliac occlusive disease (TASC, type D) operated with a totally laparoscopic aortobifemoral bypass operation and open aortobifemoral bypass operation will be followed up and the results will be compared between the two procedures on the basis of the primary endpoint, a composite endpoint defined as a combined incidence of systemic morbidity, graft thrombosis and all-cause mortality.
Secondary endpoints like length of hospital stay, operation time, bleeding time shall also be considered.
Besides short form- 36 (SF-36) shall be used for the evaluation of patients health related quality of life, preoperatively,1,3,and 6 months and 1 year post-operatively.
Early, midterm and long time results shall be followed.
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||Laparoscopic Aortic Surgery: Norwegian Experiance|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||May 2015|
|Estimated Study Completion Date :||May 2023|
Laparoscopic vs open Ygraft
Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
Procedure: Laparoscopic vs open Ygraft
Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
- Composite endpoint (All-cause mortality, graft occlusion and systemic morbidity) [ Time Frame: 2005-2015 ]
Composite endpoint defined as all-cause mortality, systemic morbidity and graft thrombosis.
In this prospective comparative cohort study 50 consecutive patients with type D atherosclerotic lesions in the aortoiliac segment were treated with laparoscopic aortobifemoral bypass operation. The group was compared with 30 patients operated with open aortobifemoral bypass operations for the same disease and period of time. The groups were compared on the basis of composite endpoint All-cause mortality, graft occlusion and systemic morbidity). Stratification analysis was performed by using Mantel-Haenszel method with the patient time model. Cox multivariate regression method was used to adjust for confounding effect after considering the proportional hazard assumption. Cox proportional cause-specific hazard regression model was used for competing risk endpoints. Comparison of survival curves was done with the help of log- rank test.
- Operative time, operative bleeding, length of hospital stay, quality of life [ Time Frame: 2005-2015 ]Linear regression model was used to control for the confounding effect of the secondary continuous outcomes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01259908
|Oslo University Hospital|
|Oslo, Norway, 0424|